Top Page
Intelligent Bio Solutions
(NASDAQ:INBS)
Intelligent Bio Solutions (INBS) vs. SPDR S&P 500 ETF (SPY)
Intelligent Bio Solutions Business Overview & Revenue Model
Intelligent Bio Solutions Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.11M | 1.26M | 0.00 | 1.98M | 188.74K |
| Gross Profit | 1.43M | 326.67K | 0.00 | 1.98M | 188.74K |
| EBITDA | -8.81M | -9.47M | 30.82K | -1.82M | -561.00K |
| Net Income | -10.16M | -10.63M | -8.31M | -7.04M | -3.16M |
Balance Sheet | |||||
| Total Assets | 13.78M | 10.35M | 12.35M | 20.40M | 2.48M |
| Cash, Cash Equivalents and Short-Term Investments | 6.30M | 1.54M | 8.24M | 12.57M | 427.27K |
| Total Debt | 871.44K | 1.34M | 0.00 | 0.00 | 5.13M |
| Total Liabilities | 5.60M | 6.67M | 5.81M | 6.85M | 7.69M |
| Stockholders Equity | 8.33M | 3.80M | 6.62M | 13.61M | -5.19M |
Cash Flow | |||||
| Free Cash Flow | -9.79M | -7.88M | -3.74M | -11.30M | -498.62K |
| Operating Cash Flow | -9.57M | -7.38M | -3.36M | -11.30M | -498.62K |
| Investing Cash Flow | -221.43K | -694.14K | -880.22K | 0.00 | -14.00K |
| Financing Cash Flow | 14.56M | 1.44M | 0.00 | 23.40M | 733.86K |
Intelligent Bio Solutions Technical Analysis
Intelligent Bio Solutions Risk Analysis
Intelligent Bio Solutions Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $21.44M | ― | -25.29% | ― | 26.67% | 44.02% | |
55 Neutral | $10.93M | ― | -126.34% | ― | 3.87% | 91.76% | |
52 Neutral | $7.94M | ― | -290.85% | ― | 78.40% | 22.41% | |
50 Neutral | AU$2.58B | 2.99 | 5.87% | 2.69% | 36.78% | 14.04% | |
49 Neutral | $6.48M | ― | -15.34% | ― | 34.33% | -153.90% | |
41 Neutral | $6.73M | ― | -809.29% | ― | ― | ― | |
26 Underperform | $3.91M | ― | -74.17% | ― | ― | ― |
Intelligent Bio Solutions Corporate Events
On July 25, 2025, Intelligent Bio Solutions Inc. entered into inducement agreements with existing warrant holders to raise approximately $3.8 million in gross proceeds. The agreements involve the exercise or prepayment of Series G and Series H-1 warrants at a reduced price, with the issuance of new Series J warrants. The proceeds will fund the completion of the company’s 510k filing with the U.S. FDA for its Fingerprint Drug Screening System and support working capital and general corporate purposes. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the transaction, which is expected to close around July 28, 2025.
On July 23, 2025, Intelligent Bio Solutions Inc. announced the successful collection of new data that enhances the security and performance of its Intelligent Fingerprinting Drug Screening System, bolstering its FDA 510(k) submission. The company completed rigorous testing to validate the system’s resilience and accuracy, positioning it strongly for FDA clearance. This advancement supports the company’s goal to enter the U.S. market in 2025 and expand its international operations, addressing the growing demand for workplace safety solutions.
On July 16, 2025, Intelligent Bio Solutions Inc. announced a global distribution agreement with Smartox LLC to introduce its SmarTest Patch drug detection product to international markets outside the U.S. and Canada. This partnership strengthens the company’s position in non-invasive drug testing solutions and aligns with its international growth strategy, opening new opportunities in the justice and rehabilitation sectors. The global drug testing market is projected to grow significantly, and this agreement provides an additional revenue stream for Intelligent Bio Solutions. The company is also focused on securing FDA clearance for its fingerprint sweat-based drug testing technology to expand its U.S. market presence.
On July 15, 2025, Intelligent Bio Solutions Inc. announced the addition of the SmarTest® Patch to its non-invasive drug testing solutions portfolio. This innovative wearable device, developed by SMARTOX®, allows for continuous drug detection through sweat over a 7 to 10-day period. The SmarTest Patch complements the company’s existing Intelligent Fingerprinting Drug Testing Solution, enhancing its product offerings and market position in non-invasive testing technologies. The new device is expected to open opportunities in markets requiring longer detection windows, particularly in justice and rehabilitation settings, thereby strengthening the company’s position as demand for non-invasive drug testing options grows.
On May 15, 2025, Intelligent Bio Solutions Inc. announced significant growth in its global operations, driven by new account acquisitions and expansion into new testing areas and sectors. The company now has over 450 active accounts across 24 countries, with notable expansion into the luxury marine sector in Europe and various sectors in Australia. These developments align with the company’s strategic plans for international expansion and strengthen its foundation ahead of entering the U.S. market.
On May 13, 2025, Intelligent Bio Solutions Inc. announced its financial results for the fiscal third quarter and nine months ended March 31, 2025. The company reported a 20% sequential quarterly revenue growth and a 91% year-over-year increase in quarterly gross profit, driven by higher-margin cartridge sales, which now account for 58% of total sales. The company added 35 new accounts, bringing its total active accounts to over 450, and continued its international growth strategy with expansions in Europe and the Middle East. The company also announced a reduction in losses due to improved cost control and operational efficiency, and introduced multilingual functionality to support global scalability.